Purchase Order 75N95024P00164
Award Date
3/13/24
Potential Completion Date
3/12/25
Potential Value
$78K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $78,300.00 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned for-profit organization. The contract is for testing compounds for the blockage of cardiac ion channels, which is a critical step in the drug development process. As a global contract research organization (CRO), Pharmaron has extensive expertise in preclinical research services, including...
This firm fixed-price purchase order, valued at $78,300.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned, for-profit organization classified as a Subcontinent Asian (Asian-Indian) American owned business. The contract is for the testing of compounds to block cardiac ion channels, with a period of performance ending on November 16, 2022. Pharmaron, a global contract research organization (CRO) specializing...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct testing of compounds for the blocking of cardiac ion channels. The period of performance is from August 7, 2020 to December 31, 2021, with a potential value of $24,795.00. The work is being performed in Louisville, Kentucky....
This is a firm fixed-price purchase order award from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Pharmaron, Inc. The $78,300.00 contract is for testing compounds to evaluate their ability to block cardiac ion channels, which is relevant to drug discovery and development. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics,...
This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) to Pharmaron, Inc. for $75,600 to conduct ion channel block, IC50 determination testing on 60 compounds over a period of 12 months. The work supports drug discovery and development efforts for the National Center for Advancing Translational Sciences (NCATS) and involves evaluating compounds for potential cardiotoxicity. The contract does not have a set-aside designation. Pharmaron is a global contract...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $113,400 contract is part of the NIH Bioanalysis Testing Services 2015-2020 IDIQ (Indefinite Delivery/Indefinite Quantity) vehicle. The work involves conducting pharmacokinetic assessments, toxicity studies, and ion channel testing services to support drug discovery and development efforts, including evaluating...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order contract valued at $10,440.00 to Pharmaron, Inc., a minority-owned, for-profit organization based in China. The contract is for a pharmacokinetic study of the drugs tamoxifen and neurotinib, with a period of performance running through October 9, 2023. Pharmaron has received over 30 prior prime contract awards...